WuXi AppTec's First Quarter Rapid Growth, Full-Year Guidance Likely to Be Raised

WuXi AppTec's just-released Q1 report shows a net profit of 4.65 billion yuan for the first quarter, a year-on-year increase of 26.68%.

The company continues to focus on and strengthen its CRDMO business model, with continuous revenue growth, while continuing to optimize production processes and operational efficiency, as well as enhancing capacity efficiency due to the growth of late-stage clinical and commercialization projects, which has improved overall profitability.

In its latest company outlook, WuXi AppTec expressed confidence in achieving full-year guidance and will continue to monitor market and business dynamics, planning to revise the guidance upwards at the appropriate time; the company's overall revenue is expected to be 51.3-53 billion yuan, with continued operating business revenue growth of 18%-22%, capital expenditure of 6.5-7.5 billion yuan, and adjusted free cash flow of 10.5-11.5 billion yuan.

GLP-1 Order Fulfillment and TIDES Eruption

Driven by the surge in global demand for weight loss drugs (GLP-1), the company's business responsible for producing the core raw materials (peptides/oligonucleotides) has become a growth engine, with an expected growth of 40% by 2026.

As of the end of last year, the company held more than 20 billion yuan in orders to be executed. A key focus for Q1 is whether the company can quickly convert these orders into actual product deliveries.

Strategic "Dieting," Large-Scale Factory Construction

The company has proactively sold or downsized those "errand" businesses with thin margins and high competition (such as agency clinical trials). In this way, the company has concentrated more money and effort into the "pharmaceutical research and development plus manufacturing" field, which has the highest profits and the deepest moats.

The company plans to invest 6.5 to 7.5 billion yuan in 2026 for land purchases and new factory construction. This level of "spending" has returned to an all-time high, sending a strong signal that the company's subsequent orders have become so numerous that the existing factories are almost unable to cope and must be expanded to handle them.

This Q1 report is crucial for verifying whether the company can return to a "growth logic" from "geopolitical disturbances," and the market focus will be on whether the GLP-1 project can drive an upward revision of full-year performance.

Valuation Repair and Risk Hedging

The current share price of WuXi AppTec is about 121.9 HKD, which still has room for repair compared to the market consensus target price (about 143-158 HKD).

Attention should be paid to the stability of the American market, which accounts for 73.1% of the company's revenue, as well as the suppression of valuation premiums by geopolitical factors.